Manelimab Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5667-10mg

Add to Compare

Be the first to review this product

Manelimab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PD-L1

Concentration

>1mg/ml

Isotype

IgG1 - lambda2

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q9NZQ7

Shipping Conditions

Blue ice

Background

ICH5667 is a research-grade, unconjugated recombinant analog of manelimab, an anti-PD-L1 (CD274 / B7-H1) monoclonal antibody in the human IgG1/lambda format. It is manufactured as a non-therapeutic biosimilar for research use only and is not the clinical drug; it is not intended for human or veterinary use. Built around the well-characterised PD-L1 target, it reproduces the antigen-binding specificity of the originator so investigators can use it as a defined, traceable tool for studying the PD-1/PD-L1 checkpoint axis. Typical applications include positive and reference controls in binding and blocking assays, benchmarking of in-house or competitor anti-PD-L1 antibodies, receptor-ligand interaction studies, and preclinical in-vitro model work. It is supplied at low endotoxin (research grade below 1 EU/mg; ultra-low options below 0.5 EU/mg) suitable for sensitive cell-based assays, and is available in bulk milligram-to-gram quantities to support screening campaigns, assay development, and scale-up. As with all ichor.bio biosimilars, the reagent is intended as a standardised research analog rather than a substitute for the approved therapeutic. PD-L1 (programmed death-ligand 1; CD274, B7-H1; UniProt Q9NZQ7) is a type I transmembrane glycoprotein of the B7 immunoglobulin superfamily. It is expressed on antigen-presenting cells, many tissues under inflammatory conditions, and is frequently upregulated on tumour cells and tumour-infiltrating myeloid cells, often driven by interferon-gamma. PD-L1 engages the inhibitory receptor PD-1 (PDCD1) on activated T cells, delivering a co-inhibitory signal that dampens T-cell receptor signalling, reduces proliferation and cytokine production, and promotes T-cell exhaustion and peripheral tolerance. PD-L1 also binds CD80 (B7-1) in cis and in trans, adding regulatory complexity. In cancer, tumour PD-L1 expression is a key mechanism of immune evasion, which is why blocking the PD-1/PD-L1 interaction is a central strategy in checkpoint-inhibitor immunotherapy and a widely studied pathway in immuno-oncology research.

Other Names

CD274

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.